Chimeric molecules to target proteins for ubiquitination and degradation

Area of Science:

• Cellular biology
• Biochemistry
• Molecular mechanisms of protein degradation

Background:

• Protein degradation is crucial for cellular regulation, with the 26S proteasome playing a key role in eukaryotes.
• Ubiquitin ligases, like the SCF complex, control protein targeting for degradation.
• Dysfunctional ubiquitin-dependent proteolysis is implicated in diseases such as cancer and neurodegeneration.

Purpose of the Study:

• To introduce and evaluate Proteolysis Targeting Chimeric Molecules (Protacs) as a novel technology for targeted protein degradation.
• To demonstrate the ability of Protacs to recruit SCF ubiquitin ligase and induce ubiquitination and degradation of target proteins.
• To assess the efficacy of Protacs in degrading specific proteins, including cancer-associated ones, in vitro and in cell-based assays.

Main Methods:

• Development of Protac technology, comprising an SCF-binding moiety and a ligand for the target protein.
• Experimental validation of Protac-mediated recruitment and degradation of methionine aminopeptidase-2 (MetAP-2) via covalent interaction.
• In vitro and cell-based experiments to assess Protac-induced degradation of estrogen and androgen receptors through noncovalent interactions.
• Testing of cell-permeable Protacs for intracellular protein degradation.

Main Results:

• Successful demonstration of Protac technology for targeted protein degradation, initiating with MetAP-2.
• Protacs effectively induced ubiquitination and degradation of cancer-promoting proteins (estrogen and androgen receptors) via noncovalent interactions.
• Cell-permeable Protacs were shown to promote degradation of target proteins within cells.
• The study provides experimental evidence for the versatility and efficacy of Protac technology.

Conclusions:

• Proteolysis Targeting Chimeric Molecules represent a powerful and versatile platform for targeted protein degradation.
• Protac technology offers a promising approach for therapeutic intervention in diseases linked to aberrant protein levels.
• Further research into Protac design and application holds significant potential for drug discovery and development.